According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., ...
Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...
Zacks.com on MSN7d
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...
SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025. It plans to buy back shares worth 5 billion euro in 2025.
Apogee Therapeutics develops therapies for inflammatory autoimmune diseases. Find out why I'm bearish on APGE stock.
Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...
The authors recommend that EoE is diagnosed based on the presence of symptoms of esophageal dysfunction and at least 15 eosinophils per high-power field on esophageal biopsy. A systematic endoscopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback